Please join us for the Canadian Amyloidosis Summit. This exciting hybrid event will provide important information and updates on the management of amyloidosis and feature national and international experts. It is a 2-day event, October 18-20 2024, at the Downtown Hyatt Regency in Toronto Ontario,...
The CANO/ACIO Conference is an opportunity for oncology nurses to connect with their peers and improve their professional knowledge in the areas of oncology nursing, patient engagement and interdisciplinary practice. This year's conference will include a workshop day, keynote presentations, joint symposia, concurrent oral sessions,...
Join us for the ultimate Immunoglobulin update for your secondary hypogammaglobulinemia patients—because sometimes even B cells need a little backup.
Over the past two decades complement research has seen a breathtaking development, and progress related to complement-mediated diseases has resulted in life-transforming advancements in patient management. Nevertheless, research and clinical translation thereof are still only at their beginnings, and there is a tremendous opportunity for...
Keith Stewart, Aaron Schimmer & Dennis Kim invite you to attend: Director's Reception 66th ASH Annual Meeting Join us for the 3rd Princess Margaret Cancer Centre Alumni Reception at ASH on Friday, December 6th from 6:00 - 8:00 PM in sunny San Diego. Come enjoy...
Time to mix and mingle with your peers and celebrate achievements in Canadian hematology. Where: Luce Lofts - 1037 J Street, San Diego, CA Date: Sunday, December 8, 2024 Time: 7:30-10:00pm LOCAL TIME Dress code: business casual All CHS members attend at no cost. REGISTER...
ISLH 2025 CALL FOR ABSTRACTS On behalf of the International Society for Laboratory Hematology (ISLH) and our partner organizations: North American Specialized Coagulation Laboratory Association (NASCOLA), Accreditation Canada (AC), and the Institute of Quality Management in Healthcare (IQMH), we are pleased to invite you and...
Key learning objectives:
∙ Explain the mechanism of action of BCMA-targeted strategies for the treatment of relapsed/refractory multiple myeloma (RRMM)
∙ Evaluate the clinical evidence with BCMA-targeted approaches for the treatment of RRMM
∙ Discuss practical considerations, including key differences between BCMA-targeted treatments, that may inform their use in RRMM